Characterization of Somatically Mutated S107 $V_{\rm H}$ 11-encoded Anti-DNA Autoantibodies Derived from Autoimmune (NZB \times NZW)F₁ Mice

By Samuel M. Behar, Daniel L. Lustgarten, Sylvie Corbet, and Matthew D. Scharff

From the Department of Cell Biology and The Irvington House Institute, Albert Einstein College of Medicine, Bronx, New York 10461

Summary

We have studied 19 S107 heavy chain variable region gene (V_{H} 11)-encoded monoclonal antibodies from NZBWF1 mice. These studies show that a single V_{H} gene can encode both antibodies to foreign antigens (anti-phosphorylcholine) and to self antigens (anti-double-stranded DNA) in the same animal. All of the anti-DNA antibodies contain many somatic mutations compared with the relevant germline genes. Since the anti-DNA antibodies were extensively somatically mutated and had undergone isotype switching, the response seems to be T cell dependent. While some of the antibodies appear to be the products of an antigen-driven and antigen-selected response, a number of characteristics of the antibodies suggest that forces other than antigen are contributing to the stimulation and selection of this response.

The serum of patients with SLE contain IgG antibodies that bind strongly to double-stranded DNA (dsDNA)¹ (1) and contribute to the glomerulonephritis that is a major cause of death in this disease (2). The potential for investigating the origins of these antibodies is greatly facilitated by the availability of lupus-prone strains of mice such as (NZB \times NZW)F₁ (NZBWF1) (3). Before the onset of detectable pathology, NZBWF1 mice produce IgM antibodies that react with DNA (4). These antibodies are usually of relatively low affinity and their V region genes have not undergone significant somatic mutation (5, 6). Since such antibodies are not associated with major pathology, they are thought to be nonpathogenic. In contrast, older autoimmune mice that have developed proteinuria and pathological changes in their kidneys have IgG anti-dsDNA antibodies in their blood and at the sites of tissue damage (3). An understanding of the molecular origins of these pathogenic autoantibodies could provide some understanding of why autoimmune lupus-prone strains of mice develop such antibodies. In particular, it would be useful to determine whether the germline genes that encode autoantibodies in autoimmune animals are different from the homologous genes in nonautoimmune mice (7), whether the same germline genes also encode antibodies against environment and self antigens, and whether the autoantibodies are specifically elicited by foreign or self antigens or are the product of a general polyclonal activation of all B cells (8).

An experimental approach to these questions was suggested by our finding that a single amino acid substitution in the S107 antiphosphorylcholine antibody converted it from an antibody that protects mice from Streptococcus pneumoniae (9) to a potentially pathogenic anti-dsDNA antibody (10). This in vitro paradigm seemed likely to be relevant to in vivo events since others had shown that S107-like anti-DNA antibodies were present in NZBWF1 and MRL/lpr mice (11, 12). Since the V_HS107 germline family consists of only four highly homologous members (13), we were able to clone and sequence all of the members of this family from both NZB and NZW mice (14, 15). We also generated and sequenced five IgG antidsDNA antibodies encoded by the V_BS107 family from an autoimmune NZBWF1 mouse and showed that they were encoded by the $V_{H}11$ member of the $V_{H}S107$ germline family (14).

Here we report the sequences and DNA binding properties of 14 additional antibodies from that same animal and three antibodies from another animal. These new sequences provide a better perspective of the $V_{\rm H}$ 11-encoded anti-DNA response. While the characteristics of some of these antibodies indicate that they are products of an antigen-driven and antigen-selected response, the sequences of others suggest that there are additional forces influencing the autoimmune response.

¹Abbreviations used in this paper: dsDNA, double stranded DNA; FW, framework; (NZB \times NZW)F₁, NZBWF1; PC, phosphorylcholine; R, replacement; S, silent; ss, single stranded DNA; V_H, heavy chain variable region gene.

Materials and Methods

4-mo-old female NZBWF1 mice were immunized intraperitoneally with 100 μ g of PC-KLH in saline and boosted with the same antigen at 6 mo of age. Fusions were done using polyethylene glycol and the NSO myeloma cell line as a fusion partner as described previously (16, 17). Hybridomas that expressed a member of the V_BS107 family were detected by RNA dot blot hybridization (18) and then cloned twice in soft agar before characterization (19).

The different V₂S107 family mAbs were tested by ELISA for binding to phosphorylcholine, cardiolipin, and influenza hemagglutinin using standard techniques (20-22). The ELISA for DNA binding (23) was done using polyvinyl round-bottomed plates (Dynatech Laboratories, Inc., Alexandria, VA) which were coated with 100 μ l of poly-L-lysine (10 μ g/ml) and incubated for 2 h at 37°C or overnight at 4°C. Afterwards, the solution was flicked out and the plates rinsed with distilled water. DNA was diluted in 1× SSC and plates were coated with 100 μ l/well and incubated overnight at 4°C. The next day the plates were washed three times with PBStween and blocked with 1% BSA-PBS. For dsDNA ELISAs, calf thymus DNA filtered through nitrocellulose to remove singlestranded regions of DNA was used at a concentration of 5 μ g/ml or bacteriophage λ DNA was used at 2.5 μ g/ml. Commercially prepared single-stranded DNA (ssDNA) (Sigma Chemical Co., St. Louis, MO) was also used at 2.5 μ g/ml. The NZBWF1 mAbs were also tested for binding to dsDNA using immunofluorescence on the microorganism Crithidia lucilae (24) using a commercially (Clinical Sciences, Whippany, NJ) prepared Crithidia slide and rhodamine $F(ab')_2$ rabbit anti-mouse κ chain antibody. Isoelectric focusing was done as described (25). Briefly, samples in 8 M urea were focused on a 4.5% polyacrylamide gel containing ampholines (LKB Instruments, Gaithersburg, MD) with a range of pH 3.0-10.0 and analyzed by Western blot (26).

The heavy and light chain variable regions of the S107 V_{μ} family-encoded anti-DNA hybridomas were sequenced by dideoxynucleotide sequencing directly from the mRNA template as described by Geliebter (27) using end-labeled synthetic oligonucleotides as primers.

 V_K Germline Cloning. Genomic DNA extracted from the livers of NZB and NZW mice was partially digested with the restriction endonuclease Mbol and ligated into EMBL3 (28). The library was screened with a 300-bp probe derived from cloned BALB/c S107B germline DNA (29). Positive plaques were purified and rescreened with an oligonucleotide probe (5' GTGCATGTAACTTACACT3') specific for a 6-bp deletion that distinguishes the V_K light chain consensus sequence of the group 2 (Table 1) antibodies from the BALB/c V_K S107B germline and the group 3 V_K sequences. One clone was amplified by the PCR, using primers containing unique restriction sites that facilitated forced subcloning of the amplified fragment into M13 (30, 31). Sequencing was done by the dideoxynucleotide chain-termination method using 2'-deoxyadenosine 5'- α -[³⁵S] thiol triphosphate and M13 vectors (31).

Results

The conversion of S107 from a protective antibody to an autoantibody indicated that the $V_{\rm H}1$ germline gene, which encodes S107, could also encode anti-dsDNA antibodies (10). The only difference between S107 and its DNA binding U4 mutant is a glutamic acid to alanine substitution at residue 35 of the heavy chain variable region (20). Crystallographic studies of another $V_{\rm H}1$ encoded PC-binding antibody (32)

and computer modeling of the S107 binding site (33) have demonstrated that glu 35 is a contact residue for the choline rather than the phosphate moiety of the phosphorylcholine (PC) molecule. This suggested that the glu to ala substitution might continue to allow binding to other phosphorylated molecules such as DNA. Our sequencing of the NZB and NZW germ line $V_{\mu}11$ genes showed that they encode a serine at residue 35 and that $V_{\mu}11$ was the germline gene for the one S107-like NZBWF1 antibody that had been reported (11, 34). Thus the germ line $V_{\mu}11$ is similar to the DNA binding mutant of $V_{\mu}1$ and can encode DNA binding proteins. The $V_{\mu}11$ gene also encodes antibodies to influenza, PC, and oxazalone in nonautoimmune strains of mice (35–40).

Taken together, these findings suggested that an examination of the antibodies encoded by the $V_{\mu}S107$ gene family in autoimmune mice might provide useful information on the molecular origins of anti-DNA antibodies and their relationship to the response to foreign antigens. We therefore immunized young NZBWF1 mice with PC-KLH and showed that their immune response was dominated by T15 (S107) antibodies that use the same genetic elements (V_H1, DFL-16.1, $J_{\mu}1$, $V_{\kappa}22$, and $J_{\kappa}5$) as the nonautoimmune BALB/c mice (reference 15 and Table 1). When such PC-immunized NZBWF1 mice had developed IgG anti-dsDNA antibodies, they were boosted with PC-KLH and their spleen cells were fused 3-4 d later. The fusions from two animals (N4 and N14) were screened by RNA dot blot (18) and 19 hybrids (Groups 1-7) expressing members of the V_BS107 family were sequenced and examined for their ability to bind various antigens. Based on the sequence of the four members of the V_HS107 germline genes from both NZB and NZW mice (14, 15, and our unpublished results), we were able to determine that all 19 of these antibodies were derived from $V_{\rm H}$ 11 germline genes (Table 1 and Fig. 2).

Antigen Binding. The 19 V_H11-encoded mAbs were examined for their ability to bind dsDNA and ssDNA using a solid phase ELISA. Four patterns of DNA binding were observed and are illustrated in Fig. 1 and summarized in Table 1, where the antibodies are grouped into families that utilize the same genetic elements and share the same junctional and N sequences (see below). In Fig. 1, N4-18 is an IgG2a antibody from a family of nine antibodies (Table 1, group 2), all of which bind dsDNA more strongly than ssDNA. Since anti-DNA binding can be detected with $<2 \mu g$ of N4-18, its binding is comparable with that of the anti-dsDNA antibodies that have been reported by others (41, 42).

N4-3 (Table 1, group 4) reacts with ssDNA and weakly, if at all, with dsDNA (Fig. 1). N14-4 is an IgG2a antibody from the second (N14) mouse (Table 1, group 1) and it binds more strongly to ssDNA than to dsDNA. Even though N4-26 is also an IgG2a antibody that is encoded by the $V_{\rm H}$ 11 gene, it does not bind dsDNA or ssDNA (Fig. 1).

Genetic Elements. By sequencing the heavy chain V regions of the 19 antibodies in groups 1–7 (Table 1), we discovered that they contain base changes that distinguish the $V_{\rm H}$ 11 germline gene from the $V_{\rm H}$ 1, $V_{\rm H}$ 3, and $V_{\rm H}$ 13 members of the S107 family in both NZB and NZW mice (43). The antibodies could be divided into groups based on their utiliza-

732 Somatic Mutation of Anti-DNA Antibodies

Group	Antibody	PC	DNA	Class	VH	D	JH	Average R/S VH	VK	JK
1	N14-4,6,8	+/-	ss>ds	IgG2a	11	FL16.1	3	4.3/0.3	VK8	2
2	N4 (9)	-	ds>ss	IgG2a	11	Q52	1	6.6/4.2	VK4,5	5
3	N4-23,38	-	ds = ss	IgG2a	11	SP2.2	2	2.0/2.5	VK4,5	4
4	N4-3,6	-	SS	IgG3	11	SP2.3	2	3/0	?	3
5	N4-24	+	-	IgM	11	SP2.3	2	1/0	VK19	5
6	N4-26	-	-	IgG2a	11	Q52	2	0	VK4,5	2
7	N4-31	_	_	IgM	11	Q52	2	0	VK8	4
8	N8-1,5,24	+	-	IgM	1	FL16.1	1		VK22	5
9	6G6	+	+	IgM	11	Q52	3		511	?
10	D42	-	+	IgG2a	11	SP2.3	1	3/0	?	5

Table 1. The Specificity and Variable Region Gene Usage of the NZBWF1 Hybridomas

The specificity and variable region gene usage of the MZBWF1 hybridomas. Group 1 hybridomas are from the N14 fusion, group 2-7 hybridomas are from the N4 fusion, and group 8 hybridomas are from the N8 fusion. Hybridoma supernatants are tested for reactivity with PC and DNA. The assignment of heavy chain variable region gene usage is based on the sequences of the relevant NZB and NZW germline genes. The D and J elements are based on sequence homology to BALB/c elements. The V_x subgroups are based on the classification of Kabat et al. (46) and for the subgroups listed, are identical to the group numbers assigned by Potter (61). The D, J_H, and J_k segments were compared to BALB/c germline sequences (46). D42 and 6G6 are two V_H11-encoded antibodies taken from the literature (11,36); their specificity is also shown.

tion of the various germline elements that form the mature V regions (Table 1). Furthermore, examination of the junctional areas in the third CDR of the heavy chain V regions, including potential N regions, and of shared somatic mutations in the V regions, indicates that each of the groups in Table 1 represent the progeny of a single B cell (35, 44, 45). For example, the heavy chains of all three antibodies from the N14 fusion (Table 1, group 1) use the FL16.1 D region and $J_{\rm H}3$, differ from the germline $V_{\rm H}11$ region by replace-



Figure 1. The binding of representative antibodies to dsDNA and ssDNA. Direct binding was measured by ELISA using culture supernatants. The supernatants were all adjusted to 50 μ g/ml and then serially diluted. All four antibodies are IgG2a and encoded by the V_H11 heavy chain gene.

733 Behar et al.

ment substitutions at residues 31, 44, 52A, and 93 (Fig. 2), and have a nongermline-encoded junctional arginine in CDR3 of the heavy gene. However, they each differ from the others by one or two base changes (Fig. 2). Their light chains are encoded by a V_K8-like gene and J_K2 and differ from the VKG15 sequence (kindly provided by Dr. P.J. Gearhart, Johns Hopkins Medical School) by six to seven bases (Fig. 3 and Table 1). The V_K differences shared by the three light chains could be polymorphisms since we do not know the germline sequence of the relevant V_K gene in NZB or NZW mice. When the DNA from these three hybridomas was examined by Southern analysis with a $J_{\rm H}$ region probe, all shared novel restriction fragments that are not present in the liver of NZB or NZW mice or in the NSO fusion partner (data not shown). Taken together, these findings suggest that these three antibodies are all derived from a single B cell clone (35, 44, 45).

Similar analysis of the rest of the antibodies made it possible to identify the other genetic elements that are associated with V_{μ} 11 in the N4 animals. As shown in Table 1, four different D and three different J segments were found associated with V_H11 in the DNA binding antibodies that were identified. Three of the four Ds were also found in the PC binding and non-DNA non-PC binding antibodies from the N4 animal. The fourth D region, DFL16.1, was present in all of the PC binding antibodies encoded by the V_H1 germline gene from a younger animal (Table 1, group 8) (15). The light chains that were found in these antibodies were also somewhat restricted in that they all had some association with the S107 family or the PC response. The light chains expressed in groups 2 and 3 (Table 1), which bind dsDNA, and in the non-DNA binding IgG2a (group 6), were V_k genes that closely resemble S107B. S107B is a light chain expressed in large amounts in the S107 tumor and cell line that has a dele-

Group	,	ų	/H	ilal	1	1	llat	c (5 a a	61	61	61	1.444	ila i	610	P	61						e	.			e	÷1		T h -	D4.	¥ 6	31
		, C	GAG	GT6	RAG	CTG	GTG	GAG	TCT	GGA	ÇGA	GGC	TTG	GTA	CAG	CCT	666	GGT 1	TCT	CTG	AGT	CTC	TCC	TGT	GCA	GCT	TCT	GGA	TTC	ACC	TTC	ACT	GAT -C-
1		6 - 8 -																								a							-C- -C-
	,	6 -			a													-8															
	1	8 - 0 -					A					AA- 		1											 -8-	•		c					 G
2	3	6 - 7 -			-C-																A				-1g 						C		
		1 - 2 -																															
	1	7 -																c -															c
1	` 2	,																								-							
•	3	8 -																															
4		3 -						•••-									-=u	uu= -															A
ŗ		- o																								*							
6	2	6 -																															
(3	1 -																															
		_		.CDA	1										11									.52A.				_54		CDR2			
		ן ד	fyr IAC	Tyr TRC	flet ATG	Ser AGC	1ep 166	Va I GTC	Arg CGC	61n CAG	Pro CCT	Pro CCA	.61y 666	Lys AAG	GCA	Leu CTT	GAG	Teg 1	 TG	Ala GCT	Leu TTG	ATT	Aca Aca	Asn AAC	Lys AAA	HTa GCT	Aøn AAT	G I Y GGT	Tyr TAC	Thr ACA	Thr ACA	GAG	Tyr TAC
1		4 - 6 -													A A									-G- -G-									
		8 -				t									A-									-6-									
	1	6 - 8 -			•	t 							a 															-A- 			G		t
	1	0 ~ 6 -			•						TT- 	•			t											 g		-A- -A-	C			a	t
2	2	7 - 1 -				-C-														 c		 -C-		G		 -T-		-A- 				a	
	1	2 - 7 -	t	 t	•	t 		•			T															-1- 						 - a	
	1	9 -				-C-						•										-C~		t	6					-*-	t		
3	2	3 - 8 -				-A- -A-																										a a	
4		3 -																									c			-8-			
		6 -				-A-																		t								a	
5	2	4 -													-																		
ž	3	1 -		- * -																													
																				_										_			
	- SF	ier IGT	R I a GCR	Ser TCT	Val GTG	Lys AAG	Giy GGT	Arg CGG	Phe TTC	Thr ACC	II. Atc	Ser TCC	Arg I AGA I	lap A DRT A	len S IAT 1	ior G ICC C	in Sa An AG	r 110 C Ato	Lei CT	u Tyr C TAT	Lei F CT	u Gii T Cai	n Net A ATG	Ren AAT	Al a GCC	Leu CTG	Arg AGR	Al a GCT	G I u GRG	Rep GAC	Ser AGT		
1		ier IGT	R I a GCR	Ser TCT	Val GTG	Lys AAC	61 y 66 T	Arg CGG	Phe TTC 	Thr ACC a	1 • ATC 	Ser TCC	Arg I AGA I	lap A DAT A	len 5 IAT 1	ier G ICC C	in Se RA AG	r c C ATC 	L.	u Tyr C TAT	Lei CT	u Gii T Cai 	n Net A ATO	8an 881 	A a GCC	Leu CTG	Aca	A a GCT 	G u GAG	Rep GRC	Ser AGT		
1		ier IGT	A I a GCR	Ser TCT	Val GTG	Lys AAG 	Giy GGT	Arg CGG 	Phe TTC 	Thr ACC 	1 e ATC 	Ser TCC	Arg I RGA I	lep A DRT F	lan S IAT 1	ier G ICC C	in Se Ra Ro 	r 110 C ATC 	Le CT	u Tyr C TAT 		u Gii T Cai 	n Net A ATG 	Ren AAT	Al a 600	Leu CTG 	firg AGR 	Al a GCT 	G u GAG 	Rep GRC 	Ser AGT 		
1	- SF 6 8 0	ier IGT	A a GCR 	Ser 1 TCT	- Val	Lys AAG	Giy GGT	Arg CGG 	Phe TTC 	Thr ACC 	1 I • ATC	Ser TCC 	Arg RGA	lep A DRT F	lan S IAT 1 	ier G	In Se RA AG	r 110 c Att		u Tyr C TAT		u Gii	A ATO	Aan AAT	file GCC	Leu CTG 	Arg AGA 	Al a GCT 	G I u GAG 	Rep GRC 	Ser AGT 		
1 1 1 2 2		ier iGT	R a 6CP 	Ser TCT	Val	Lys AAG 	Giy Got	Arg CGG 	Phe TTC 	Thr RCC 	1 I • ATC	Ser TCC 	Arg (RGA	GCA	lan S IAT 1 	ier G icc C	In Se RA AG 		Le.	u Tyr c TAT		G II	- Net A ATC 	Ren AA1	file GCC	Leu CTG 	Arg ACA 	Al a GCT C	G I u GAG 	Rep GAC 	Ser AGT 		
1 1 1 3 2 2	- SF	ier igt ic-		Ser TCT 	Ual GTG 	Lys AAG	GI y GGT	Arg CGG 	Phe TTC 	Thr ACC 	1 • ATC 	Ser TCC 	Arg (RGA		lan S IAT 1 		In Se RA RG 			u Tyr C TAT		G CA 		Ren AA1	Ala GCC	Leu CTG	AcA	Al a GCT C 	G I u GAG 	Rep GRC 	Ser AGT 		
1 1 3 2 2 1		ier iGT	R a GCR 	Ser 1 TCT				Arg CGG 	Phe TTC 	Thr ACC 	1 • ATC 	Ser TCC 	Arg RGA 	-Gc -	len S IAT 1 		In Se RA AG 			u Tyr c Tai 				Ren AA1	Al a GCC		Arg AGA 	Al a GCT C R	G I u GAG 	Rep GAC 	Ser AGT G		
1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	468 68D671279 3	ier iGT iC-	R a GCR 	Ser TCT 	Val 616			Ang CGG 	Phe TTC 		II.e	Ser .	Arg (RGA 		len S IAT 1 		In Se AA AG 			u Tyr c Tar 		G () T CAI		Ren AAT	Ala GCC		Arg AGA 	A I a GCT C R	G I U GAG 	Rep GRC 	Ser AGT G 		
1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		ier IGT	R a GCR) Ser 1 TCT 	· Val			Arg CGG 	Phe TTC 	Thr ACC	11. ATC 		Arg (RGA)	lep A DRT F 	Sen S IAT 1 		In Se RR AC			u Tyr c Tai 				Ren AAT 	Ala GCC 		Arg AGA 	Ala GCT C R 	Giu GAC 	Rap GRC 	Ser AGT G 		
1 1 2 2 2 1 1 1 1 3 2 3 3 4		ier igT igC-	R a GCR 	Ser TCT 	· Val			Arg CGG 	Phe TTC 		11. ATC 	Ser 1 TCC	Arg RGA 	lap A DRT F 	len S IAT 1 		In Se RR AG 			u Tyr c Tai 				Ren A A1	Alla GCC 		Arg AGR 	Ala GCT C R 	G I u GAG 	Rep GAC	Ser AGT G 		
1 1 3 2 2 2 2 3 3 4 5 2	168 68D671279 38 36 1				· Val	Lys AAG 		Arg CGG 	Phe TTC	Thr ACC	III • ATC		Ang (RGA 		lan S IAT 1 		In Se RA A0 			u Tyr C Tai 		G G G G G G G G G G		Ren AA1	Ala GCC 		Arg AGA 	Ala GCT C A 	G I u GAG 	Asp GRC 	Ser AGT G 		
1 1 2 2 2 2 1 1 1 1 1 1 1 1 1 5 2 6 2 7 3	168 680671279 38 36 461							Ang CGG 	Phe TTC 	Thr.C.		Ser	Arg (RGA) 	lep f int f 	len S IAT 1 		In Se RA AC 					G () C		Ren Anti-	Alla GCC 		Arg AGA 	Ala GCT C A 		Rep GRC 	Ser AGT 		
I I 3 2 2 2 1 1 1 1 1 1 1 1 1 5 2 3 3 4 5 2 7 3		ier igT iC-	R I a GCR 		· Uali			Arg CGG 	Phe TTC	Thr. ACC	11. ATC 	Ser 7 TCC	Arg RGA 	Aep fi DRT F 	Sen S IAT 1 	ier 6 rcc c 	In Se AR AG 					G () () () () () () () () () (- Net A ATC 	Ren Anti- 	Ala GCC 		Arg AdA 	Ala GCT C R 	G I U GAC 	Rep GAC 	Ser AGT G G -		
1 1 3 2 2 2 2 1 1 1 1 1 1 1 3 3 3 4 5 2 6 2 7 3			R 1a 6CR 		Vali Gig 	Lue And 	61y 661 	Arg 	Phe TTC 			Ser 1 TCC	Arg RGA 	Aep A DRT F 	Arg	Sier 6 (CC C 	In Se RA AG 			u Tyr C TAI 		Giy	Gin Gin	Ren AAT 	Alla GCC 	Leu CTG 	Rrg AGA 	Ala GCT C R R 	Giu GAC 	Rep GRC 	Ser AGT G 	ita I	
1 1 3 2 2 2 2 3 4 5 2 3 4 5 2 3 4	168 680671279 38 36 161 ft.	ier ig ic-	R la GCR 	Ser 7	· Vali 616 	Lye RAG 	Gly GGT 	Arg CGG 	Phe TTC 	Thr ACC		Ser TCC 	Arg RGA 	Ren Ran Ran Ran Ran Ran	Arg Arg Arg	ier 6 ier 7 ier 7 ie	In Se RA AG 	P 114 C ATC 	Le. CT 	Tyr TAC		Giy Giy Giy Giy	G in CRA	8 en AA1 	Ala GCC 	Leu CTG 	Arg AGA 	Ale GCT C R 	G I u GAG GAG 	Rep GRC 	Ser AGT 	ita CC JI	НЗ
I I 3 2 2 2 2 3 3 4 5 2 7 3 4 1 1	168 68D671279 38 36 161 168	ier ig ig ig ig ig ig ig ig ig ig	R a GCR 	Ser 7	· Vali 616 	Lye Ang 	GIU GGT 	Arg 	Phe TTC 	Thr ACC	1110 ATC 	Ser TCC 	Arg I Arg I 	Ren R	Arg Arg Arg		In Se AA AC		Le. CT-	u Tyr c Tai 		Giy Giy Giy	Gin Gin 	A	Alla GCC GCC 	Leu CTG 	Arg AGA 	Ale GCT R R RCT	G I u GAG GAG 	Rep GRC 	Ser AGT G 	11a 12C JI 	НЗ
1 1 3 2 2 2 1 1 1 3 4 5 2 6 7 3 1	168 680671279 38 36 161 168		R la GCR 	Ser 7	- Uali GTG 	Lye and 	GIU GGT 	Arg Arg Arg Arg	Phe TTC 		11.0 ATC	Ser	Arg Arg Arg Arg 	Asp A 	Arg Arg Arg	JH JH	In Se RA A0 		Le. CTI 	U Type		Giy Giy Giy Giy Giy	Gin CAA	6 i y 6 i y	Alla GCC 	Leu CTG 	Arg AGA 	Ala GCT 	Giu GAG 	Asp GRC 	Ser AGT	0 11 	Н3
I I 3 2 2 2 2 1 1 1 3 3 4 5 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	168 68 067 1279 38 36 161 168 69		R la GCR 	Ser 7	- Turi - Turi 	Lye and a second	GIU GGT GGT 	Arg 	Phe TIC 	Thr. ACC		Ser	Arg I AGA I	Asen Asen Asen Asen Asen Asen Asen Asen	Image: Second	Ser 6 CC C 	In Se RA AC 		101 Alo GAT	u Tyr C Tai 	Trp TGG TGG	Giy Giy Giy GGC	Gin GCA GCA GCA	6 l y 6 G l y 6 G G G 6 G G G 6 G G G 7 G G G G	Alla GCC 	Lou CTG 	Arg AAAA	Ala GCT C	G I u GAG GAG 	Asp GRC 	Ser AGT G -	6 11 	H3
I I 3 2 2 2 1 1 1 3 3 4 1 5 2 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			R la GCR 	Ser 1 1 TCT 	Tyr	Lys And 	GIU GGT 	Arg Arg Arg Arg Arg	Phe TTC 	Thr ACC	11. ATC 	Ser 1 TCC 	Arg I Arg I	Aep A DRT F -Gc - 	Arg Arg Arg	JH JH Son Tr Con Son Tr Con Son Tr Con Son T	In Se RR RG 		Le L	U Tyr 		Giy Giy Giy Giy GGC	G In CRA GCA GCA GCA GCA GCA GCA GCA	61y 61y 600 61y 600 61y 600 61y	Thr ACT Thr ACC Thr ACC	Levu CTG 	AGA AGA 	Al c GCT 	GIU GAG GAG C C C C C C C C C C C C C C C C	Rep GRC 	Ser AGT -	1 a 1 	H3
1 1 2 2 2 2 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2	468 680 671279 38 36 461 468 680671		R a GCR 	Ser 1 TCT 1 TCT 2	· Ual	Lys And 	Giy GGT 	Arg CGG 	Phe TTC 	Thr ACC	11. ATC 	Ser	Arg I RGA 1 	Asp A -GC - 	Arg Arg Arg Arg Arg Arg	JH JH JH Son Tr C C Son	In Se RR RG 		Lee C CTi 	u Tyr c TAI 		Giy Giy Giy Giy Giy Giy Giy	G In CRA GCA GCA GCA GCA GCA GCA GCA GCA GCA GC	61 y 60 y 60 y 60 y 60 y 60 y 60 y 60 y 60	Thr ACC	Leu CTG 	AGA AGA AGA AGA AGA AGA AGA AGA AGA AGA	Alo GCT	Giu GAG GAG 	Rep GRC 	Ser AGT	11 a 11 	H3
1 1 2 2 2 2 2 3 3 4 5 2 2 2 2 2 2 2 2 2 2 2 2 2	468 680 67 1 2 7 9 3 8 3 6 4 6 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 1 6 8 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 4 6 1 1 1 1 1 6 8 6 8 6 8 0 6 7 1 2 7 9 3 8 3 6 8 8 0 6 7 1 2 7 9 3 8 3 6 8 8 0 6 7 1 2 7 9 3 8 3 6 8 8 0 6 7 1 2 7 9 3 8 3 6 8 8 0 6 7 1 2 7 9 3 8 8 3 6 8 8 0 6 7 1 2 7 9 3 8 3 6 8 8 0 6 7 1 2 7 9 3 8 8 3 6 8 8 0 6 7 1 2 7 9 3 8 8 3 6 8 8 0 6 7 1 2 7 9 3 8 8 3 6 8 8 0 6 7 1 2 7 9 3 8 8 3 6 8 8 0 6 7 1 2 7 9 3 8 8 3 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8		R a GCR 	Ser 1 1 Ser 1 1 TCT 	· Ual	Lys AAG 	Giy GGT 	Arg -	Phe TTC 	Thr ACC	110 ATC 	Ser 1 TCC	Arg I RGA I 	Aep A BAT F 	Arg Arg Arg Arg Arg Arg Arg Arg	JH JH JH JH JH JH JH JH JH JH JH JH JH J	In Se RA AG 	- 116 - 417 	101 Ala GGT	U Tyr 		61y GGC	Gin Gin Gin Gin Gin CRA Gin CRA Gin CRA Gin CRA Gin CRA Gin CRA CRA CRA CRA CRA CRA CRA CRA CRA CRA	61y 666 675 675 675 675 675 675 675 675 675	Ala GCC 	Levu CTG 	Rrg AGA AGA 	Alo GCT 	Giu GAG GAG 	Rep GRC 	Ser AGT	10 001	H3
1 1 2 2 2 2 2 3 3 2 3 4 5 6 2 3 1 1 1 1 1 1 1 1 1 1 1 1 1	468 680 671 279 38 36 461 1 468 680 671 279 37 36 36 461 1 1 1 680 680 671 1 279 36 36 461 1 1 1 680 680 671 279 36 36 461 1 1 1 680 680 667 1 279 36 36 461 1 1 1 680 680 667 1 279 36 36 461 1 1 1 363 680 667 1 279 363 <		R a GCR 	Ser 1 101	Tyr Tar	Lye RAG 	Giy GGT 	Arg Arg Arg	Phe TTC 	Thr ACC	110 ATC 	Ser	Arg (RGA) 	Asp A and A	Arg Arg Arg Arg 	JH JH JH JH 	In Se RA AGO 	- 116 C ATC 	Lee C CTi 	u Tyr C TA 		Giy Giy Giy Gic Giy Gic Gir Gir Gir Gir Gir Gir Gir Gir Gir Gir	6 in CAA CAA CAA CAA CAA CAA CAA CA	6 1 y 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	Ala GCC <	Lev CTG 	Rrg AGA AGA 	Alo GCT R 	Giu GAG GAG 	Rep GRC 	Ser A G G G G G G G G G G G 		H3
I I 2 2 2 2 3 4 5 2 2 3 4 1 1 1 1 1 1 1 1 1 1 1 1 1	468 680 6712 79 38 36 461 168 680 6712 79 38 36 161 168 680 6712 79 38 36 161 168 680 6712 79 38 36 161 168 680 6712 79 38 36 161 168 680 6712 79 38 36 161 168 680 6712 79 38 36 161 168 680 6712 79 38 36 161 168 680 6712 79 38 36 161 168 680 6712 79 38 36 161 168 680 6712 79 38 36 161 163 680 6712 79 38 36 161 163 680 6712 79 380 360 360 360 360 360 360 360 360 360		R a GCR GCR 	Ser 1 (17)	Turn Turn Turn Turn Tac	Lye and 	Gly GGT 	Arg Arg Arg Arg Arg	Phe TTC 	Thr ACC	11.0 ATC 	Ser	Arg (RGA) 	Ren Arg	Arg Arg Arg Arg Arg Arg Arg Arg	JH JH JH JH The JH JH JH JH JH JH JH JH JH JH JH JH JH	In Se RA AGO 	- 116 C ATT 	Le CT	u Tyr C TA 		Giy Gig Gig Gig Gig Gig Gig Gig Gig Gig Gig	Gin	6 i y 6 6 6 1 y 6 6 6 1 y 6 6 6 1 y 6 6 6 1 y 6 6 6 1 y 6 6 6 1 y 6 6 6 1 y 6 6 6 1 y 6 6 6 1 y 6 6 1 y 6 6 1 y 6 6 1 y 6 6 1 y 6 1	Ala GCC <	Leug CTG CTG CTG CTG CTG CTG CTG CTG CTG CTG	Ring R RGR R R RGR R R RGR R R RGR R R R R R R R R R R R R R R R R R R R	Alo GCT 	Giu GAG GAG 	Rap GRC 	Ser A Thr A Ser A Ser A Ser A Ser A	L 201	H3 H1
1 1 2 2 2 1 1 1 1 2 2 2 1 1 1 1 1 1 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1				Ser 1	Typ	Lye AAG 	GIU GGT 	Arg 	Phe TIC	Thr ACC	11. ATC 	Ser 1 TCC 	Bry I have been set of the set of	Aen Arg CG T	Jenn S IAT 1 IAT 1<	JH JH JH The form of the second secon	In Se RA AG 	- 116 C ATT 	Lee CT	Tyr Tyr TAC	Trp TGG TGG TT TGG TGG TGG	Giy Giy Gig Gig Gig Gig Gig Gig Gig Gig Gig Gig	Gin Gin CAR GCR GCR GCR GCR GCR GCR GCR GCR GCR GC	6 i y 6 i y	Ala GCC 	Leu CTG CTG 	Rrg AGA	Alo GCT 	Giu GAG 	Rep GRC 	Ser A G -		H3 H1
I I I I I I I I I I I I I I				Ser 1	Tyr Trac	Lye And 	Gly GGT	Arg CGG 	Phe TTC 		11. ATC 	Ser 1 TCC 	Arg I RGA I Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly	Asp Asp	Jenn S IAT 1 IAT	JH JH JH JH JH JH JH Levu Levu Levu Levu	In Se AR AG 	- 116 C ATT 	Le CT.	Tyr Tyr Tyr Tac Since Si	Trp TGG Trp TGG Trp TGG	Giy Giy Gig Gig Gig Gig Gig Gig Gig Gig Gig Gig	Gin	61y 61y 61y 600 61y 600 61y 600 61y 600 61y 600	Ala GCC 	Leu CTG 	Rrg AGA AGA 	Alo GCT 	Giu GAG 	Rep GAC 	Ser A G 		H3 H1 H2
I I 2 2 2 2 2 1 1 1 2 2 2 2 2 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2	568 680671279 38 36 461 1468 680671279 38 36		Ria GCR 	Ser 1	Tur TAC	Lye And 	GIU GGU GGU GGU GGU GGU GGU A	Arg Arg Arg Arg Arg	Phe TTC 	Thr ACC	11.0 ATC 	Ser 1 TCC 	Arg I RGA I GI GI GI GI GI GI GI GI GI GI GI GI GI	Asn Asn Ang Correction Correctio	Arg Arg RG Arg Giy Giy Giy Giy Giy Composition	JH JH JH JH The Tr J JH JH JH JH JH JH JH JH JH JH JH JH J	In Se ARA RO 		101 Rep GAC T	Tyr Tyr Tyr Tyr Tyr Tar Tar Tar Tar Tar Tar Tar Ta	Trp TGG 	61 y 61 y 63 y 64 y 65 y 66 y	Gin Gran	6 l y 6 GGG 6 J y 6 GGG 6 GGGG 6 GGGG 6 GGGG 6 GGGG 6 GGGG 6 GGG 6	Ala GCC 	Leu CTG 	Rrg AGA	A 10 GCT 	Giu GAG 	Rep GAC 	Ser RGT 	la 1 	H3 H1 H2
I I I I I I I I I I I I I I	168 68 067 1279 38 36 161 168 68067 1279 38 36 16		Rid 607	Ser 1	Tur Trac	Lye and a second	Gly GGL GGL GGL GGL GGL GGL GGL GGL GGL A A	Arg Arg Arg Arg Arg	Phe TTC 	Thr ACC	11. ATC 	Ser 1 TCC 	Arg I AGA GI GI GI GI GI GI GI GI GI GI GI GI GI	App A p -Ge - -Ge -	Arg Arg Arg GG C	JH JH JH The form of the second secon	In Se AA AG A A AG 		Lee C CT- C T- C - C - C - C - C - C - C - C - C - C	Typ Typ Tac 	Trp TGG 	Giy Giy Gig Gig Gig Gig Gig Gig Gig Gig Gig Gig	Gin (CAA)	61y 661y 660 61y 660 61y 660 61y 660 61y 660 61y 60 61y 60 60 61y 60 60 61y 60 60 61y 60 60 60 70 70 70 70 70 70 70 70 70 70 70 70 70	Ala GCC	Leu CT CTG 	Arg AGA	Ale GCT 	Giu GAG	Rep GRC 	Ser 6 	11 a J 11 a J	H3 H1 H2 H2

734 Somatic Mutation of Anti-DNA Antibodies

tion of two V region amino acids at the VJ junction and does not associate with the S107 heavy chain and is therefore not secreted (29). The group 2 and 3 light chains are members of the V_k4 or V_k5 families and are very similar to each other and to S107B in BALB/c (Fig. 3). The light chain used by the three N14 anti-DNA antibodies (group 1) belongs to the Vk8 subgroup and closely resembles the McPC 603 light chain, which is found in many PC binding antibodies, especially those made in response to immunization with Proteus morgani (47). These light chains are most homologous to V_kG15 , which in combination with J_k2 , forms the light chain used by HPCG15 (38), a BALB/c anti-PC mAb encoded by $V_{\rm H}$ 11. This is particularly interesting in light of the ability of the group 1 antibodies to bind PC, albeit weakly. A very similar light chain is present in the IgM (group 7) antibody from the N4 fusion. The V_k 19 like light chain that is found in N4-24, a V_H11-encoded anti-PC antibody (group 5), has to our knowledge not previously been associated with the anti-PC response. However, it does have the Tyr at residue 94, Pro at residue 95, and Leu at residue 96, which are thought to be important for PC binding (48).

Somatic Mutations. The N14 (group 1) hybridomas bind ssDNA better than dsDNA (Fig. 1), react with Crithidia, and also bind weakly to PC, cardiolipin, the influenza hemagglutinin, and protamine (data not shown). They each have four to six replacement substitutions in their heavy chain V regions (Table 2) with an average frequency of 2.4% in the CDRs and 1.0% in their framework (FW) regions. They have a replacement (R) to silent (S) ratio in both their CDRs and FWs that is >1.5:1, which is found in most FWs (Table 2) (44). Based on these criteria (35, 44, 45), the three N14 antibodies represent the progeny of single B cell that have undergone a moderate amount of somatic mutation and could have been driven to proliferate and selected for amplification by antigen.

Using similar criteria, N4-23 and 38 (Table 1, group 3), which bind dsDNA and ssDNA, also appear to be derived from a single parental B cell (Figs. 2 and 3). They contain a few somatic mutations but do not have a high R/S ratio (Table 2). N4-3 and 6 are IgG3 antibodies that bind ssDNA and are also related to each other by shared junctional sequences, light chains, and a few common and unique replacements (Table 1, Figs. 2 and 3). The C-A substitution in J_n2, which is used by N4-23, 38, 3, 6, 24, 26, and 31, is probably a polymorphism since it is found in all NZBWF1 H chains that use J_n2.

The nine group 2 antibodies are the largest and most interesting family from the N4 fusion. Their isotype is IgG2a (Table 1) and several are cationic with isoelectric points between 7.2 and 8.0 (data not shown). They vary greatly in their binding to dsDNA (Fig. 4) and do not bind PC or cardiolipin. All nine antibodies appear to be the progeny of a

Table 2. R/S Ratios in Heavy Chains

Group	Antibody	CDR	FW	Total
1	N14-4	2/0	2/0	4/0 4
	N14-6	2/0	2/1	4/1 5
	N14-8	3/0	4/0	7/0 7
3	N4-23	1/1	1/1	2/2 4
	N4-38	1/2	1/1	2/3 5
4	N4-3	3/0	0/0	3/0 3
	N4-6	1/0	0/0	1/0 1

R/S ratios in the heavy chains of groups 1, 3, and 4. The ratio of mutations that result in an amino acid replacement (R) to those that are silent (S) mutations are tabulated for the FWs and the CDRs as defined by Kabat et al. (46).

single B cell based on (a) utilization of $V_{H}11$, D_{Q52} , and $J_{H}1$ genetic elements to form the heavy chain V region; (b) the same apparent N sequences and a junctional recombination site that converts the first amino acid of $J_{H}1$ from a tyrosine (TAC) to an asparagine (AAC); and (c) the use of the same V_{K} germline gene and $J_{K}5$ (Table 1 and Figs. 2 and 3). In addition, many of these hybridomas share the same novel nonproductive rearrangements and those that lack these fragments have presumably lost them due to segregation after fusion (data not shown).

All members of this family have many somatic mutations in both the heavy and light chain genes (Fig. 2-4). While there are some shared mutations among subsets of two or three antibodies, it is not possible to organize them in a manner in which more than two form a branch of a family tree and most seem to represent distinct sublineages of the parental B cell. For example, N4-16, 10, 36, and 27 share a G-A substitution that encodes a glycine (GGT) instead of the germline encoded aspartic acid (GAT) at residue 54 in CDR2. However, each of these antibodies has distinctive mutations shared with other members of group 2, making it difficult to determine if they are on the same branch of the family tree or if there are many parallel mutations (49). Similarly, N4-18, 10, and 1 all share a G-T change in the second residue of J and N4-10 and 1 both have a G-A change in that same codon (Fig. 2). If the G-T in N4-18 occurred first, then it would be the parent of N4-10 and 1. However, N4-18 contains many base changes that are not present in N4-1 or 10. It is possible that the parent of N4-18 was also the parent of N4-1 and 10 but this is difficult to prove. Parenthetically, if the G-A had occurred first in N4-10 and 1, it would have created a nonsense mutation (TAG) but the G-T substitution protects from that.

Figure 2. Heavy chain variable region sequences of NZBWF1 V_{μ} 11-encoded antibodies. The heavy chain variable region sequences for the 19 antibodies from the N4 and N14 fusions are shown compared with the NZB and NZW V_{μ} 11 germline sequences. The NZB and NZW V_{μ} 11 are identical to each other (14, 43). The N and D sequences from the hybridomas are compared with the consensus sequences derived from each group. The BALB/c germline J_{μ} 1, J_{μ} 2, and J_{μ} 3 sequences are shown for comparison. Numbering is according to Kabat et al. (46). The symbols are as follows: (-) identity; (-) probable identity; (u) purine; (y) pyrimidine; (lower case letter) silent mutation; (upper case letter) replacement mutation; (space) ambiguous base.

Grau	IP		VK																					23						
			Giu	Ran	Val	Leu	Thr	Gin	Ser	Pro	Ala	11.1	let S	Ser A	la S	ier P	ro G	ly Gi	Lya	Val	Thr	llet.	Thr	Cya	Sen	Ala	Ser	Ser S	Ser	
		16					-T-												1 ANU											
		18									-8-				T- •												G			
		10																A-									6		A	
2		27					-1-																							
		1.										•			-• -	·T														
		17																												
		19																												
	S10)7B			g							a -	()	-c -		1g -	C-:	,											
3		23			g											- G		~							G					
3 6		30 · 26	c	-1-	9											·u														
v			•															:												
			Rap	110	Val	liet	Ser	Gln	Ser	Pro	Ser	Ser L	eu f	ila V	al S	er A	la G	ly Gli	i Lya	Val	Thr	llet	Ser	Cys	Lya	Ser	Ser	Gin	Ser	Leu
	G	515	GAC	AT?	GTG	ATG	TCA	CAG	TCT	CCA	TCC	TCC C	TG (SCT G	TG T	CA G	CA G	GA GA	G AAG	GTC	ACT	ATG	ACC	TGC	888	TCC	AGT	CAG I	AGT	CTG
1		6		t																			t							
		8		=-t			*						·			- * -							t							
						HI	llal	Sen	Sen	Sen	Tun	Mat k		30 [nn T	un G		101		Sen	The	Sen	Pno	1		Tee		Tue	8.00	[hn	Sen
							GTR		•••	AGT	TAC	ATG C	AC 1	IGG T	AC C	AG C	AG A	AG TC	A AGO	ACC	TCC	CCC	AAA	CIC	TGG	ATT	TAT	GAC	ACA .	TCC
		16																						6						~
		18					 0						-t -										~	G						
		36																												
2		27																						G					-t -	
		1																					~							
		17																												
		19																									-6-			
	S10)7B						AGT	TCC			T							· G	G-t				-C-	-1-		C	AGG ·		
3		23					9	AGT	TCC	-C-		T							• G-t	G							CT-	AG-		
3		38					9	HUI	Tee	-0-		 							- U-l - G	u				 86a				HU- ·		
v																			·											
			Leu	flar	Se	· Arg	Th	Arg	l Lya	Asn	Tyr	Leu	Ala	Trp	Phe	Gin	ûln	Lys Pr	•0 G1	y Gir	Ser	Pro	Lys	Pro	Leu	110	Tyr	Trp	Ala	Ser
	G	515	CTC	880	; AG	r Rga	ACC	CGR		AAC	TAC	TTG	GCT	TGG		CAG	CAC	AAA CI	CA 66	G CAC	S TCT	CCT	888	000	CTG	ATC	TRC	TGG	GCA	TCC
1		6													-8-									-1-						
•		8		=											-A-			1	•					-1-		-=-			- •	-
					-																									
		Lue	Le	LCUH 11 A 1	2 a Se		u Ua	I Pr	6 G I	u Arr	Phi	San	Gtu	Sen	Gla	Sen	Glu	Asn S	en T	r≱ ar⊳Se	: n l e	u Th		. S.	n Se	r He	• 61		. 61.	
		AAA	i ct	G GC	T TO	T GG	A GT	c cc	A GG	Ť CG	TT	RGT	GGC	AGT	GGG	TCT	GGA	AAC 1	CT T	AC TO	T CT	C AC	G AT	C AG	C AG	C AT	G 68	6 GC1	GAF	- -
	16																			G-					8					•
																														-
	18																							- A	A				•	
	18 10 36		 	 					 			 										 		- A	A C 					-
2	18 10 36 27		 		 						· · · · ·									G-		 		- A	A C 					-
2	18 10 36 27 1		 																	- 6-				- A	A C 					-
2	18 10 36 27 1 2																			- G-		 		- A	A	 A				-
2	18 10 36 27 1 2 17 19		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	 															- G-				- A	A C 	 A 				-
2	18 10 36 27 1 2 17 19 \$107B			· · · · · · · · · · · · · · · · · · ·	 				 											G-				- R	A C 	 A - G-				-
2	18 10 36 27 1 2 17 19 \$1078 23				 				 t t	A														- A	A C 	 A t G-	C			-
2 3 3	18 10 36 27 1 2 17 19 \$1078 23 38 26		 T T						 t t t															- A	A C 	 A t G- t G- t G-				-
2 3 3 6	18 10 36 27 1 2 17 19 \$1078 23 38 26		 T T						 t t t t t	A							9							- A	A C 	 A t G t G t G	C			-
2 3 3 6	18 10 36 27 1 2 17 19 \$1078 23 38 26		 T	 				 	 t t t t t t	A			 61y		 6 1 y					G	 			- A A A A A	A C 	 A t G t G t G t G				
2 3 3 6	18 10 36 27 1 2 17 19 \$1078 23 38 26 615			 				 	 	A			 Giy GGC	Ser AGT	 Gly GGA	Ser TCT		 			 	u Th		- A 	A C 	 A t G t G t G t G T GT				
2 3 3 6	18 10 36 27 1 2 17 19 51078 23 38 26 615 4 6				u Se				 t t t t t t t t t t t t t	A	· · · · · · · · · · · · · · · · · · ·		 Giy GCC		 Giy GGA	Ser TCT					 			- A	A	 t G t G T GT 			GI (
2 3 3 6 1	18 10 36 27 1 2 17 19 51078 23 38 26 6 15 4 6 8				u Se					A-	Ph(G I y	Ser TCT			ap P AT T		r Le	u Th C AC		- A	A	 t G- 		Al (
2 3 3 6	18 10 36 27 1 2 17 19 51078 23 38 26 6 515 4 6 8				u Se A TQ						Ph(G		u ThC		- A	A	 A r Va T GT 		A l d G G C 1		
2 3 3 6	18 10 36 27 1 2 17 19 51078 23 38 26 615 4 6 8								 t t t t t t 	 	Ph(• Thr • Control of the second			 Gly GGA Pro					 	 		 r 	- A	A	 				
2 3 3 6	18 10 36 27 1 2 17 19 51078 23 38 26 615 4 6 8						 G GT T TA		 t	 	Photos 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	• Thr • Control of the second		 Ser AGT Tyr TAC	 Gly GGA Pro CCA					 	 		 	- A	A	 t G t G 				
2 3 3 6	18 10 366 27 1 2 17 1 2 17 19 8 1078 23 38 26 23 38 26 6 15 4 6 8 8				u Sec					 	Ph(• Thr • • • Thr • ACA • • • Thr • ACA • • • Thr • ACA •	 Giy GGC		Giy Pro CCR	 Ser TCT 	 					u The second sec		- A	A	 r Va T 		Alico An Ali		
2 3 3 6 1	18 10 366 27 1 2 17 19 23 38 23 38 26 515 4 6 6 5 5 4 6 8 8 8 16			 	u Sec 85 0 Th C AC						Ph(Giy GGA Pro CCA				sp Pl				 	- A	A	 			GIU GIU GIU	
2 3 3 6 1	18 10 366 27 1 2 17 19 23 38 26 515 4 6 8 8 16 18 10 36 36 36 38 38 26 38 38 38 26 38 38 26 38 38 26 38 26 38 26 38 26 27 19 23 23 24 23 25 25 25 25 25 25 25 25 25 25				u Se A TQ B C A C A C A C A C A C A C A C A					• Gir • Cir •	Photos		Giy Giy Goo Giy Goo		Gly GGA CCA						a GI		 	- A	A	 		Al (6) Al (A	GIU GIU GIU	
2 3 3 6 1	18 10 36 27 1 2 17 19 23 38 26 515 4 6 8 16 18 10 36 27 19 23 38 8 26 51 51 51 51 51 51 51 51 51 51									• Gir 	Pho Pho TTC TTC Git Git Git Git Git Git Git Git Con Con Con Con Con Con Con Con Con Con				Gly Gly CCA				sp Pi		a G1		 	- A	A			Ange		
2 3 3 6 1	18 10 36 27 1 2 17 19 23 38 26 6 5 6 15 4 6 8 16 18 10 36 27 19 21 7 19 21 23 38 26 27 19 21 23 38 26 27 19 21 23 23 23 23 23 23 23 23 23 23			g GI G GA 	u Se 85 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	r Typ		r Cy C TG C TG C TG		• Gir 	Photos 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	• Thr • • Thr • ACA • • Thr • • • Thr •		Ser RGT Tyr TAC -T-	Gly GGA CCA				sp Pi		a Gi			- A	A			Arg 601		
2 3 3 6 1	18 10 10 10 10 10 10 10 10 10 10			g GI G GA G GA G GA G GA G GA G GA G GA G		r Typ		r Cyg		• Gir • Gir • CGC • CCC • CCCC • CCC • CCCC • CCCC • CCCC • CCCC • CCCC • CCCC • CCCC • CCCC • CCCC • CCCCC • CCCCC • CCCCCCCCCC	Pho TTC TTC GGG GGG GGG	Ser 1			Gly GGA						a Gi			- A	A		u Ly:	A reg 		
2 3 3 6 1	18 10 10 27 1 2 2 17 19 5107B 23 38 26 6 6 7 1 6 8 8 16 18 10 19 5107B 23 38 26 8 8 1 19 5107B 23 38 26 27 19 5107B 23 38 26 27 19 5107B 23 38 26 27 19 5107B 23 38 26 27 19 5107B 23 38 26 27 19 5107B 23 38 26 27 20 23 38 26 27 20 27 28 28 28 26 27 28 28 28 26 28 28 28 28 26 28 28 28 28 28 28 28 28 28 28							r C UG		• GIn • CGC • CCC • CCCC • CCCCC • CCCCC • CCCCCCCC	Pho TTC TTC GGG GGG GGG	J Ser J Ser			Gly GGA CCA						a GI	y C AC		- A	A		u Ly:	A Regional A Control A Con		
2 3 3 6 1	18 10 27 1 27 17 12 27 17 19 23 38 26 6 6 8 6 16 18 10 23 38 26 7 1 12 23 38 26 7 10 19 23 38 26 26 10 23 23 24 25 25 25 25 25 25 25 25 25 25							r Cy G		• GIn • GIN	Phu The second s	Ser 1		Ser 700 8 Ser 700 700 700 700 700 700 700 700 700 70	Gly GGA CCA				he G G		a Gij T CT T CT T CT T CT T CT T CT T CT T C	u C AC		- A	A			Arcs 		
2 3 3 6 1 2 3	18 10 10 27 1 27 17 19 19 23 38 26 23 38 26 615 4 6 8 16 18 18 10 23 38 26 27 12 23 38 26 26 27 12 23 38 26 27 23 38 26 27 23 38 26 27 27 23 38 26 27 27 23 38 26 26 27 27 23 38 26 26 26 27 27 27 28 28 28 26 26 26 26 26 26 26 26 26 26						y Va G GT 	r Cy Cy C		• GIR • GIR	Photometric control of the second sec	J Ser 	Giy Giy Gig Go 	Ser 7 7 8 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	Gly GGA CCA CCA CCA		 		he G G		a Gij T CT T CT T CT T CT T CT T CT T CT T C	u C AC		- A	A			Arrg 		
2 3 3 6 1 2 3 3 6	18 10 10 27 1 27 17 12 23 38 26 515 4 6 8 6 8 6 16 18 10 36 26 16 18 10 27 17 10 23 38 26 515 17 17 17 17 17 17 17 17 17 17				u See B C B C C C C C C C C C C C C C		y Va G GT 			• GIn 	Photometric Control Co	Ser 1	Giyy Gigg God 	Typr TAC 	Gly GGA	 Ser TCT 			sp Pi Pi At T T		a Giji T CT T CT T CT T GG S S S S S S S S S S S S S S S S S S	y g G		A A A A A A A A A A A A A A A A A A A	A			Arg 		
2 3 3 6 1 2 3 3 6	18 10 10 27 1 27 17 17 17 18 23 38 26 6 8 6 16 18 16 18 10 23 38 26 26 27 17 17 17 17 23 38 26 26 27 23 28 26 27 23 28 26 27 27 23 28 26 26 27 27 23 28 26 26 26 27 23 28 26 26 26 27 23 28 26 26 26 26 26 26 26 26 26 26				u See 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		y Va G G	r Cyg		• GIn •	Image: Constraint of the second sec	J Ser J Ser	Giy Giy GGC 	Typr TAC 	Giy GGA 	 Ser TCT 			sp P P AT T 		a Giji T CT G Gi G Gi G Gi G G G G G G G G G G G G	y G A C		A A A A A A A A A A A A A A A A A A A	A			Arg 		
2 3 3 6 1 2 3 3 6	18 10 10 27 1 27 17 17 17 23 38 26 6 6 8 6 6 8 7 16 8 8 16 8 8 16 8 8 16 12 12 12 12 12 12 12 17 17 17 17 17 17 17 17 17 17			9 GI G G G G G G G G G G G G G G G G G G			y Va G G 	r CyG TG		• GIr 	Phi Gli	J Ser G AGT	Giy Giy GGC 		Gly GGA 	JK2			sp Pi Di Si		a Gij T CT T CT T CT T CT T G T G T G T G T G T G T G T G T G T			A A A A A A A A A A A A A A A A A A A	A C			Arrg		
2 3 3 6 1 2 3 3 6	188 106 27 1 2 17 17 17 23 38 26 26 38 26 6 36 27 6 17 6 8 23 38 26 6 16 18 10 36 27 7 1 2 3 38 26 26 26 27 7 17 12 23 38 26 26 26 26 27 7 17 12 23 26 26 26 27 7 17 12 23 26 26 27 7 17 23 26 26 27 7 17 23 26 26 26 27 7 17 23 26 26 26 27 7 17 23 26 26 26 26 27 7 20 27 20 20 20 20 20 20 20 20 20 20 20 20 20									• GIn • GIN	Photo Control	Ser 1 Ser 1 Se	Giy GGC GGC GGC GGC GGC GGC GGC GGC GGC GGC	Ser AGT 	Gly GGA	Ser TCT			sp Pi		a Gi T CT T CT T CT T GG T GG T GG T GG T GG	yg			A C 			Arcsi 		
2 3 3 6 1 2 3 3 6	18 10 10 27 1 27 17 12 23 38 26 23 38 26 21 2 17 19 23 38 26 27 19 23 38 26 27 19 23 26 27 19 23 26 23 26 23 26 27 19 23 26 26 27 19 20 23 26 26 27 19 20 20 20 20 20 20 20 20 20 20										Ph(T	y Ser 	Giyg GGC GGC GGC GGC GGC GGC GGC GGC GGC GG	Ser AGT TAC TTAC TTAC TAC TAC TAC TAC TAC TAC	Gly GGA	 			he G TC G XX - XX - XX - he G TC G		a GI T GG T GG T GG T GG G GG G GG	y g g			A			A Arcs 		
2 3 3 6 1 2 3 3 6 1	18 10 10 27 1 27 17 12 23 38 26 26 26 26 27 17 12 23 38 26 26 26 26 26 26 27 27 27 27 27 27 27 27 27 27			g GI G GA 			y Va G GT 			• GII • · · · · · · · · · · · · · · · · · · ·	Photometric control of the second sec	y Ser 	Giyy GGC 	Tyr Tyr Tyr Tar Tur Tar Tur Tar Tur Tar Tur Tar Tur Tar Tur Tar Tur Tar Tur Tur Tur Tur Tur Tur Tur Tu	Giy GGA 	 -			Image: Second		a GI T CT T CT T CT T CT T GG T GG T GG T GG	y g G		A A A A A A A A A A A A A A A A A A A	A		U Ly:	Arg 		



Figure 4. Direct binding to dsDNA. The nine group 2 V_H11-encoded anti-dsDNA antibodies were tested for dsDNA binding by a direct ELISA. The culture supernatants were adjusted to 20 μ g/ml and then serially diluted.

We also examined the switch sites of N4 hybridomas to identify members of a single branch of the family tree. For example, only N4-36 and 17 have identical switch recombination sites when probed with a γ_{2a} switch site probe (data not shown). They also show a shared single silent mutation at residue 58 but have no other shared mutations. This suggests that they were derived from a common precursor which switched after acquiring the shared mutation at residue 58 and then underwent subsequent divisions and acquired a number of independent mutations all following switching. Similar observations have been reported by others (50, 51) and suggest that point mutations continue to arise following switching from IgM to IgG.

Since we were unable to organize this group of nine antibodies into a genealogy that contained more than two to three members per branch, we attempted to examine their relationship to each other by comparing their binding to dsDNA (Fig. 4). N4-16, 18, 10, and 36 show easily detectable binding to dsDNA at 1-2 μ g/ml. However, they do not have many more V region mutations than N4-17 and 19, which bind weakly. It is worth noting that N4-17 and 19 would probably not have been identified if we had used antigen binding to screen the hybridomas since even at 10 μ g/ml, which is a reasonably high concentration of antibody for an average hybridoma, their DNA binding is barely above the background. N4-1, 2, and 27 have the least number of somatic mutations and require 5-10 μ g/ml to give detectable binding. Thus, the number of V_H mutations is not directly proportional to the binding of dsDNA.

It was possible that N4-17 and 19 had initially acquired higher binding due to somatic mutation and that the process of maturation continued and resulted in a decrease in their binding. One might expect that this would be reflected in the location of the replacement mutations in these antibodies. However, N4-17 does not have any replacement substitution in its heavy chain CDRs and the replacement substitutions in the CDRs of N4-19 are not shared with any of the highest binders suggesting that these are antibodies that never underwent somatic mutation that would increase their binding to dsDNA or a cross reactive antigen. The heavy chain CDRs of N4-10 and N4-1 have R to S mutations that exceed the 2.9:1 ratio which is thought to occur randomly (52), but many of the other antibodies of this group have R/S ratios in their heavy chains CDRs, which are less than the 1.5:1 ratio found in the FW residues of antibodies in general (Fig. 4) (44).

The NZW germline V_k gene, which encodes the light chains of these nine antibodies, was cloned by taking advantage of its homology with the S107B V_K gene segment (29). The relevant NZB and NZW genes did not differ by restriction analysis and hybridization with various oligonucleotides including one that spans the deletion (data not shown). The sequence of the NZW V_K gene (Fig. 3) is identical to the consensus sequence that was derived from all nine light chains (14). The most remarkable finding is that N4-16 and 18 have very high R/S ratios in the FWs of their light chains (Fig. 4). These FW changes in the light chains of N4-16 and 18 are distributed throughout the linear sequences of these antibodies (Fig. 3). It is interesting to note that there are many replacement substitutions in the FW of all of the light chains except N4-10.

Since we screened for the expression of $V_{\rm H}S107$ by RNA dot blot, we also identified antibodies from the N4 animal that did not bind DNA (Table 1). The nonDNA binders use the same genetic elements as the DNA binders but in different combinations (Table 1). N4-24 utilizes the $V_{\rm H}11$ gene, does not bind DNA, but does bind PC. Other $V_{\rm H}11$ -encoded PC-

Figure 3. Light chain variable region sequences of $V_{\rm H}$ 11 anti-DNA antibodies. The light chain variable region sequences for 14 anti-dsDNA antibodies from the N4 and N14 fusions are shown compared with the NZW-cloned $V_{\rm K}$ gene (top line), as well as the BALB/c S107 and $V_{\rm K}$ G15 light chains (nucleotide sequence of $V_{\rm K}$ G15 kindly provided by Dr. P.J. Gearhart). The J_K segment is compared with the BALB/c germline J_K2 and J_K5 sequence. The symbols are as follows: (x) deleted base; (-) identity; (=) probable identity; (lower case letter) silent mutation; (upper case letter) replacement mutation; (space) ambiguous base.

binding antibodies have been reported. HPCG15, a BALB/c V_{μ} 11-encoded anti-PC antibody has undergone extensive somatic mutation (38), while V_{μ} 11 anti-PC antibodies from other mouse strains, such as CBA/J (53) and CLA-2/Cn (37), are germline encoded.

N4-24 shows that the same heavy chain variable region gene can encode antibodies that react with DNA and with a foreign antigen at the same time in a single mouse. N4-26 does not bind DNA or PC and does not have any somatic mutations in the $V_{\rm H}$ 11 gene (Fig. 2). N4-31 has a single conservative (Val to Ile) amino acid substitution in the third FW.

Discussion

We have determined the variable region sequences of 19 antibodies expressing the S107 V_H11 germline from two NZBWF1 mice. 16 of these antibodies bind DNA and are the products of four different B cell clones. Based on serum studies and screening of a number of fusions, we know that V_{μ} 11-encoded antibodies represent \sim 5-30% of the antidsDNA antibodies made by older autoimmune NZBWF1 mice (reference 15 and our unpublished studies). However, by focusing our attention on V_H11-encoded antibodies, we were able to determine the sequences of the relevant germline genes and to screen hybridomas for V_{H} expression in order to recover antibodies that might have been missed if we had only looked for those that bound antigen. Although the animals were immunized with PC, and many of the antibodies used genetic elements associated with the anti-PC response, further experiments will have to be done to determine the influence of the prior immunization of these animals with PC-KLH and the boost with this antigen immediately preceding the fusions.

All of the anti-DNA antibodies that we have identified have undergone significant somatic mutation. It is not clear whether somatic mutation is required to create pathogenic autoantibodies. For example, Naparstek et al. (54) have shown that a germline-encoded antibody from a nonautoimmune mouse combined with both a foreign antigen and DNA, and that the progeny of this antibody lost their DNA binding as they underwent somatic mutation and affinity maturation for the foreign antigen. No V_H11 germline-encoded DNA binding antibodies were identified in the fusions that we have carried out. This suggests that either the germline V_H11 cannot achieve sufficient affinity for dsDNA irrespective of the N and D sequences with which it is associated or that B cells expressing high affinity germline-encoded V_H11 autoantibodies are suppressed. The latter is more likely since Shafner et al. (55) have shown that $V_{H}11$ germline-encoded antibodies with strong DNA binding can be detected in BALB/c mice whose suppressive mechanism has been blocked.

The presence of replacement substitution in the CDRs and the ratio of R to S mutations can be used to deduce whether a particular antibody response is driven by antigen and whether the antigen selectively promotes the outgrowth of B cells making higher affinity antibodies (35, 44, 45). Some of the antibodies that we have identified have high R/S ratios in their CDRs suggesting that the amino acid substitutions in

their antigen binding site has increased their ability to bind antigen. The analysis of the nine antibodies in group 2 suggests that some of the B cells in this clone are the product of such an antigen-driven and selected response and that the antigen is either dsDNA or crossreactive with it, i.e., the members of this group with the lowest number of replacement substitutions in their CDRs bind DNA poorly and the highest binders have a number of replacement substitutions in their binding sites. This suggests that, at least for this B cell clone, somatic mutation is required to achieve significant binding to DNA. In addition, these antibodies have some of the characteristics that have been suggested by others (34, 42, 56, 57) to promote binding to DNA. For example, there are arginines and asparagines in the third CDR of this group. N4-18, which is one of the highest binding members of the group, has acquired an additional arginine in that region through somatic mutation. However, at least in the assays that we have used, the binding of N4-18 to dsDNA is no better than that of N4-16 (Fig. 4), which does not have that particular somatic mutation. Eilat et al. (34) and Shlomchik et al. (56) have noted that some anti-DNA antibodies express their D regions in unusual reading frames, have inverted Ds, or are the product of D-D recombination. These characteristics are not present in the V_H11-encoded antibodies that we have studied, confirming that some anti-DNA antibodies can acquire strong binding without unusual forms of D (56).

The presence of somatic mutations and the IgG2a isotype indicate that helper T cells have interacted with B cells in order to generate the anti-DNA antibodies that we have studied. It is more difficult to deduce the role of antigen. However, it is worth noting that at least in one instance, somatic mutation has led to a B cell clone that started out producing antibodies to only ssDNA to produce an antibody that also reacted with dsDNA (56), again suggesting a role for dsDNA, or something highly crossreactive with it, in driving the anti-DNA response. While the antibodies in group 1 and group 4, and some of the antibodies in group 2, have high R/S ratios in their CDRs, most of the antibodies in group 2 and group 3 do not have these characteristics. This is also true of some of the anti-DNA antibodies that have been described by others (56).

Since we screened our fusions for V region utilization rather than antigen binding, it is difficult to compare our results with most of the studies in the literature where the antibodies have been identified by their ability to bind antigen. Nevertheless, genealogies resembling the group 2 antibodies with their many independent sublineages have been observed in responses to haptens (50, 59). Manser (50), who also screened fusions for V region utilization, reported a large family of antibodies that were made in response to a foreign antigen in which there were many R substitutions in the FWs of the light chains. That particular clone is unusual, in that it may have lost the expression of its surface Ig due to a nonsense mutation early in its propagation, undergone a period of unselected mutations, then reverted to the nonsense mutation and gone on to expand the clone under the influence of antigen (50).

In spite of these precedents in other studies, it is unusual to find a single clone that contains antibodies like N4-17 and N4-19, which bind weakly to antigen (59), that has progeny with many independent sublineages, and whose antibodies have so many R substitutions in the FW of the light chains. It is possible that some of these changes in the FW of the light chains have a direct effect upon the conformation of the antigen-binding site. However, it is also possible that antiidiotypic antibodies or idiotype-specific T cells (60) contributed to the expansion of the B cell producing the group 2 antibodies and perhaps some of the other antibodies we have identified. Further studies will be required to determine whether the peculiarities of the group 2 antibodies are a reflection of abnormalities that result in the production of autoantibodies by autoimmune mice or whether similar responses will also be found in the response of nonautoimmune mice to foreign antigens.

This work was supported by a grant from the National Cancer Institute (CA-05973). M. D. Scharff is the occupant of the The Harry Eagle Chair in Cancer Research from the National Women's Division of Albert Einstein College of Medicine. S. M. Behar and D. L. Lustgarten are medical scientist trainees supported by the National Institute of General Medical Sciences (NIGMS) grant T32GM7288. S. Corbet was as a recipient of the Miriam and Benedict Wolf Fellowship from the Cancer Research Institute of New York.

Address correspondence to Matthew D. Scharff, Department of Cell Biology and The Irvington House Institute, Albert Einstein College of Medicine, Bronx, NY 10461.

Received for publication 14 May 1990 and in revised form 13 December 1990.

References

- 1. Koffler, D. 1984. Immunopathogenesis of systemic lupus erythematosus. Annu. Rev. Med. 25:149.
- 2. Estes, D., and C.L. Christian. 1971. The natural history of systemic lupus erythematosus. Adv. Immunol. 37:369.
- 3. Dixon, F.J., and A.N. Theofilopoulos. 1985. Murine models of systemic lupus erythematosus. Adv. Immunol. 37:269.
- Steward, M.W., and F.C. Hay. 1976. Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in NZB/W F1 mice. *Clin. Exp. Immunol.* 26:363.
- 5. Madio, M.P., J. Carlson, J. Cataldo, A. Ucci, P. Migliorini, and O. Pankewycz. 1987. Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J. Immunol. 138:2883.
- 6. Trepicchio, W., Jr., A. Maruya, and K.J. Barrett. 1987. The heavy chain genes of a lupus anti-DNA autoantibody are encoded in the germ line of a nonautoimmune strain of mouse and conserved in strains of mice polymorphic for this gene locus. J. Immunol. 139:3139.
- 7. Kopfler, R., F.J. Dixon, and A.N. Theofilopoulos. 1987. The genetic origin of autoantibodies. *Immunol. Today.* 8:374.
- 8. Klinman, D.M., and A.D. Steinberg. 1987. Systemic autoimmune disease arises from polyclonal B cell activation. J. Exp. Med. 165:1755.
- Briles, D.E., C. Forman, S. Hodak, and J.L. Claffin. 1982. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against *Streptococcus pneumoniae*. J. Exp. Med. 156:1177.
- Diamond, B., and M.D. Scharff. 1984. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. *Proc. Natl. Acad. Sci. USA*. 81:5841.
- Eliat, D., M. Hochberg, J. Pumphrey, and S. Rudikoff. 1984. Monoclonal antibodies to DNA and RNA from NZB/NZW F1 mice: antigenic specificities and NH₂ terminal acid sequences. J. Immunol. 133:489.

- Trepicchio, W., Jr., and K.J. Barrett. 1987. Eleven MRL lpr/lpr anti-DNA autoantibodies are encoded by genes from four V_H gene families: a potentially biased usage of V_H genes. J. Immunol. 138:2323.
- Crews, S., J. Griffin, H. Huang, K. Calame, and L. Hood. 1981. A single V_H gene segment encodes the immune response to phosphorylcholine: somatic mutation is correlated with the class of the antibody. *Cell.* 25:59.
- Behar, S.M., and M.D. Scharff. 1988. Somatic diversification of the S107 (T15) V_H11 germ-line gene that encodes antidsDNA antibodies in (NZB × NZW) F1 mice. Proc. Natl. Acad. Sci. USA. 85:3970.
- Behar, S.M., S. Corbet, B. Diamond, and M.D. Scharff. 1989. The molecular origin of anti-DNA antibodies. *International Reviews of Immunology*. 5:23.
- Fazekas de St Groth, S., and D. Scheidegger. 1980. Production of monoclonal antibodies: strategy and tactics. J. Immunol. Methods. 35:1.
- Clark, M.R., and C. Milstein. 1981. Expression of spleen cell immunoglobulin phenotype in hybrids with myeloma cell lines. *Somatic Cell Genet.* 7:657.
- Manser, T., and M.L. Gefter. 1984. Isolation of hybridomas expressing a specific heavy chain variable gene segments by using a screening technique that detects mRNA sequences in whole cell lysates. *Proc. Natl. Acad. Sci. USA*. 81:2470.
- Zack, D.J., and M.D. Scharff. 1984. The identification of somatic mutations in immunoglobulin expression and structure. *In* Single-Cell Monitoring Systems. A. Ansari and F.J. De Serres, editors. Plenum Publishing Corp., New York. 233-264.
- Giusti, A.M., N.C. Chien, D.J. Zack, S.-U. Shin, and M.D. Scharff. 1987. Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base chain in its heavy chain variable region. *Proc. Natl. Acad. Sci. USA*. 84:2926.

739 Behar et al.

- Eilat, D., A.Y. Zlotnick, and R. Fischel. 1986. Evaluation of the cross-reaction between anti-DNA and anti-cardiolipin antibodies in SLE and experimental animals. *Clin. Exp. Immunol.* 65:269.
- Staudt, L.M., and W. Gerhard. 1983. Generation of an antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. J. Exp. Med. 157:687.
- Naperstek, Y., D. Duggan, A. Schattner, M.P. Madaio, F. Goni, B. Frangione, B.D. Stollar, E.A. Kabat, and R.S. Schwartz. 1985. Immunochemical similarities between monoclonal antibacterial Waldenstrom's macroglobulins and monoclonal anti-DNA lupus autoantibodies. J. Exp. Med. 161:1525.
- Arden, L.A., E.R. de Groot, and T.E.W. Feltkamp. 1975. Immunology of DNA. III. Crithidia lucilae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann. N.Y. Acad Sci. 254:505.
- 25. Olsson, I., and T. Laas. 1981. Isoelectric focusing in agarose under denaturing conditions. J. Chromatgr. 215:373.
- Burnette, W.N. 1981. Western blotting: electrophoretic transfer of proteins from sodium decyl sulfate polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 112:681.
- 27. Geliebter, J. 1987. Dideoxynucleotide sequencing of RNA and uncloned cDNA. Focus (Idaho). 9:1.
- Frischauf, A.-M., S. Brenner, L. Barnett, and G. Cesareni. 1983. Lambda replacement vectors carrying polylinker sequences. J. Mol. Biol. 170:827.
- Kwan, S.-P., E.E. Max, J.G. Seidman, P. Leder, and M.D. Scharff. 1981. Two kappa immunoglobulin genes are expressed in the myeloma S107. *Cell.* 26:57.
- Scharf, S.J., M.A. Innis, D.H. Gelfand, J.J. Sninsky, and T.J. White. 1990. PCR Protocols. Academic Press, Inc., Orlando, FL. 84 pp.
- 31. Sanger, F., A.R. Coulson, B.G. Barrell, A.J.H. Smith, and B.A. Roe. 1980. Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing. J. Mol. Biol. 143:161.
- 32. Segal, D.M., E.A. Padlan, G.H. Cohen, S. Rudikoff, M. Potter, and D.R. Davies. 1974. The three-dimensional structure of a phosphorylcholine binding mouse immunoglobulin Fab and the nature of the antigen-binding site. Proc. Natl. Acad. Sci. USA. 71:4298.
- 33. Chien, N.C., V.A. Roberts, A.M. Giusti, M.D. Scharff, and E.D. Getzoff. 1989. Significant structural and functional change of an antigen-binding site by a distinct amino substitution: proposal of a structural mechanism. *Proc. Natl. Acad. Sci. USA*. 86:5532.
- Eilat, D., D.M. Webster, and A.R. Rees. 1988. V regions of anti-DNA and anti-RNA autoantibodies from NZB/NZW F1 mice. J. Immunol. 141:1745.
- Clarke, S.H., K. Huppi, D. Ruezinsky, L. Staudt, W. Gerhard and M. Weigert. 1985. Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J. Exp. Med. 161:687.
- Clarke, S.H., J.L. Claffin, and S. Rudikoff. 1982. Polymorphisms in immunoglobulin heavy chains suggesting gene conversion. Proc. Natl. Acad. Sci. USA. 79:3280.
- 37. Hilbert, D.M., and M.P. Cancro. 1988. Characterization of an inbred mouse exhibiting low responsiveness to phosphorylcholine. J. Immunol. 140:4364.
- Gearhart, P.J., D.D. Johnson, R. Douglas, and L. Hood. 1981. IgG antibodies to phosphorylcholine exhibit more diversity than their IgM counterparts. *Nature (Lond.)*. 291:29.
- 39. Griffiths, G.M., C. Berek, M. Kaartinen, and C. Milstein. 1984.

Somatic mutation and the maturation of immune response to 2-phenyl oxazolone. *Nature (Lond.).* 312:271.

- Clafin, J.L., and J. Berry. 1988. Genetics of the phosphocholinespecific antibody response to Streptococcus pneumoniae. Germline but not mutated T15 antibodies are dominantly selected. J. Immunol. 141:4012.
- Lafar, E.M., J. Rauch, C. Andrzejewski, Jr., D. Mudd, B. Furie, B. Furie, R.S. Schwartz, and B.D. Stollar. 1981. Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids. J. Exp. Med. 153:987.
- Shlomchik, M.J., A.H. Aucoin, D.S. Pisetsky, and M.G. Weigert. 1987. Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse. *Proc. Natl. Acad. Sci. USA*. 84:9150.
- Behar, S.M. 1989. The impact of somatic mutation and environmental antigens and the origin of anti-dsDNA antibodies. Thesis, Albert Einstein College of Medicine, New York. pp. 1–225.
- Shlomchik, M.J., A. Marshak-Rothstein, C.B. Wolfowicz, T.G. Rothstein, and W.G. Weigert. 1987. The role of clonal selection and somatic mutation in auto immunity. *Nature (Lond.)*. 32:805.
- Allen, D., A. Cumano, R. Dildrop, C. Kocks, K. Rajewsky, N. Rajewsky, J. Roes, F. Sablitzky, and M. Siekevitz. 1987. Timing, genetic requirements, and functional consequences of somatic hypermutation during B-cell development. *Immunol. Rev.* 96:5.
- Kabat, E.A., TT. Wu, H. Bilofsky, M. Reid-Miller, H.M. Perry, and K.S. Gottesman. 1987. Sequences of proteins of immunological interest. U.S. Dept. of Health and Human Services. Washington, DC. pp. 1–804.
- Claffin, L.J., J. Berry, D. Flaherty, and W. Dunnick. 1987. Somatic evolution of diversity among anti-phosphocholine antibodies induced with *Proteus morganii*. J. Immunol. 138:3060.
- Rudikoff, S. 1983. Immunoglobulin structure-function correlates: antigen binding and idiotypes. Contemp. Top. Mol. Immunol. 169:209.
- Berek, C., and C. Milstein. 1987. Mutation drift and repertoire shift in the maturation of the immune response. *Immunol. Rev.* 96:23.
- Manser, T. 1989. Evolution of antibody structure during the immune response. The differentiation potential of a single B lymphocyte. J. Exp. Med. 170:1211.
- Shan, H., M. Shlomchik, and M. Weigert. 1990. Heavy chain class switch does not terminate somatic mutation. J. Exp. Med. 172:531.
- Jukes, T.H., and J.L. King. 1979. Evolutionary nucleotide replacements in DNA. *Nature (Lond.).* 281:605.
- Ferguson, S.E., S. Rudikoff, and B.A. Osborne. 1988. Interaction and sequence diversity among T15 V_H genes in CBA/J mice. J. Exp. Med. 168:1339.
- Naparstek, Y., J. Andre-Schwartz, T. Manser, L.J. Wysocki, L. Breitman, B.D. Stollar, M. Gefter, and R.S. Schwartz. 1986. A single germline V_H gene segment of normal A/J mice encodes autoantibodies characteristic of systemic lupus erythematosus. J. Exp. Med. 164:614.
- 55. Shafner, R., G. Kleiner, A. Turken, G. Papazian, and B. Diamond. J. Immunol. In press.
- Shlomchik, M., M. Mascelli, H. Shan, M.Z. Radic, D. Pisetsky, A. Marshak-Rothstein, and M. Weigert. 1990. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J. Exp. Med. 171:265.
- 57. Marion, T.M., A.L.M. Bothwell, D.E. Briles, and C.A.

Janeway. 1989. IgG anti-DNA auto-antibodies within an individual autoimmune mouse are the products of clonal selection. J. Immunol. 142:4269.

- 58. Blier, P.R., and A.L.M. Bothwell. 1987. A limited number of B cell lines generates the heterogeneity of a secondary immune response. J. Immunol. 139:3996.
- 59. Manser, T., Parhami-Seren, M. Margolis, and M. Gefter. 1987. Somatically mutated forms of a major anti-p-azophenylarsonate antibody variable region with drastically reduced affinity for p-azophenylarsonate. J. Exp. Med. 166:1456.
- Mendlovic, S., S. Brooke, Y. Shoenfeld, M. Ben-Basset, A. Mushovo, R. Bakimer, and E. Mozes. 1988. Induction of a systemic lupus erythematosis-like disease in mice by a common human anti-DNA idiotype. *Proc. Natl. Acad. Sci. USA*. 85:2264.
- Potter, M., J.B. Newell, S. Rudikoff, and E. Haber. 1982. Classification of mouse V_k groups based on a partial amino acid sequence to the first irvarcant typhophane: impact of 14 new sequences from IgG myeloma proteins. *Mol. Immunol.* 19:1619.